Caprelsa (vandetanib)
An approved treatment for Medullary Thyroid Cancer and Familial Medullary Thyroid Carcinoma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Vandetanib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Vandetanib
- Brand name
- Caprelsa
- Development code
- ZD6474
- Drug class
- Multi-kinase inhibitor
- Manufacturer
- Genzyme Corporation, a Sanofi company
- How it's taken
- Oral tablet, once a day
A once-daily pill for medullary thyroid cancer that is causing symptoms or growing and cannot be removed by surgery or has spread[1].
We'll email you when Caprelsa's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Vandetanib fits
Caprelsa (vandetanib) is a once-daily kinase inhibitor approved since 2011 for medullary thyroid cancer that is causing symptoms or growing and cannot be removed by surgery or has spread, and its label does not require a RET mutation[1][2].
- The Caprelsa label asks doctors to use it in slow-growing medullary thyroid cancer without symptoms only after careful consideration of its risks, and 90% of the patients in its main trial had already had their thyroid removed[1].
- Cometriq (cabozantinib) capsules are the other multi-kinase inhibitor approved for progressive, metastatic medullary thyroid cancer[6].
- Retevmo (selpercatinib) is approved for advanced or metastatic medullary thyroid cancer with a RET mutation in adults and children 2 and older[7].
- Gavreto (pralsetinib) no longer has a medullary thyroid cancer use, because the FDA removed that accelerated approval indication on July 20, 2023 at Genentech's request[9][8]. Neither the Caprelsa nor the Cometriq label reports a trial comparing the 2 drugs directly.
- In medullary thyroid cancer, the LIBRETTO-531 trial compared Retevmo with a doctor's choice of cabozantinib or vandetanib in people who had not taken a kinase inhibitor, and progression-free survival was longer on Retevmo (hazard ratio 0.28)[7].
- Anyone weighing Caprelsa can ask their oncologist whether the cancer carries a RET mutation and how the heart rhythm checks would fit into their care.
How Vandetanib works
Medullary thyroid cancer starts in the thyroid's C cells, the cells that make the hormone calcitonin. Many of these cancers are driven by a change in the RET gene, which keeps a growth signal switched on. Vandetanib blocks the tyrosine kinase activity of RET, of the VEGF receptors that tumors use to grow new blood vessels, and of the EGF receptor, along with several other kinases (BRK, TIE2 and members of the EPH and Src families)[1].
In laboratory and mouse studies, it cut the growth of new tumor blood vessels and slowed tumor growth and spread[1]. The Caprelsa label does not require a RET test before treatment. Vandetanib leaves the body slowly, and the Medication Guide says side effects can continue after treatment stops[1].
Side effects and safety
- QT prolongation and torsades de pointes. not started when the QTcF is above 450ms; an ECG plus potassium, calcium, magnesium and TSH at the start, at 2 to 4 weeks, at 8 to 12 weeks and every 3 months after; held when the QTcF passes 500ms
- Severe skin reactions. toxic epidermal necrolysis and Stevens-Johnson syndrome, some fatal; photosensitivity can occur during treatment and up to 4 months after it stops
- Interstitial lung disease. lung inflammation, including deaths; Caprelsa is paused for new or worse breathing symptoms and stopped if it is confirmed
- Ischemic cerebrovascular events. blocked blood flow to the brain, which occurred in 1.3% on Caprelsa against 0% on placebo in the randomized trial, including deaths
- Serious bleeding. including deaths; not given after recent coughing up of half a teaspoon or more of blood
- Heart failure. including deaths, and it may not reverse when Caprelsa stops
- Diarrhea. grade 3 or worse in 11%; electrolytes and ECGs are checked more often during diarrhea
- Underactive thyroid. 49% needed more thyroid hormone replacement, against 17% on placebo
- High blood pressure. including hypertensive crisis; Caprelsa is not restarted if blood pressure cannot be controlled
- Reversible posterior leukoencephalopathy syndrome (RPLS). brain swelling shown on MRI, with seizures, headache, vision changes or confusion
- Kidney failure. a lower starting dose with moderate kidney impairment; not recommended with severe impairment or with moderate or severe liver impairment
- Wound healing. held at least 1 month before elective surgery and for at least 2 weeks after major surgery
- Osteonecrosis of the jaw. added in May 2025; an oral exam before and during treatment, and Caprelsa is held 1 month before dental surgery
- Pregnancy and breastfeeding. can harm an unborn baby; contraception for women and for men with female partners during treatment and for 4 months after, and no breastfeeding for the same time
- ECG and blood potassium, calcium, magnesium and TSH at the start, at 2 to 4 weeks, at 8 to 12 weeks, then every 3 months
- The same checks again after a dose cut for QT prolongation or a break of more than 2 weeks
- Potassium kept at 4mEq/L or higher, and calcium and magnesium in the normal range
- Blood pressure throughout treatment
- An oral exam before and during treatment
- An eye exam with a slit lamp for anyone who reports vision changes
Caprelsa carries a boxed warning: it can prolong the QT interval, and torsades de pointes and sudden death have occurred[1]. The label says not to use it in people with low calcium, potassium or magnesium or long QT syndrome, and Caprelsa is contraindicated in congenital long QT syndrome[1]. In the randomized trial, 14% on Caprelsa had a prolonged QT on their ECG against 1% on placebo, and the label's footnote reports that 69% had a QTcF over 450ms and 7% over 500ms[1].
Other label warnings cover severe skin reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome, sun sensitivity lasting up to 4 months after stopping, lung inflammation, blocked blood flow to the brain, called ischemic cerebrovascular events (1.3% against 0%), serious bleeding, heart failure, severe diarrhea (grade 3 or worse in 11%), high blood pressure, a brain swelling syndrome called RPLS, kidney failure, slow wound healing, osteonecrosis of the jaw and harm to an unborn baby[1].
In the trial of 231 people on Caprelsa and 99 on placebo, side effects in more than 20% and at least 5 points more common than placebo were diarrhea or colitis (57% against 27%), rash (53% against 12%), acne-like rash (35% against 7%), high blood pressure (33% against 5%), nausea (33% against 16%), headache (26% against 9%), upper respiratory infections (23% against 16%), decreased appetite (21% against 12%) and abdominal pain (21% against 11%)[1].
Lab changes included low calcium (57% against 25%), raised ALT, a liver enzyme (51% against 19%) and low blood sugar (24% against 7%)[1]. Side effects led 12% on Caprelsa to stop treatment, against 3.0% on placebo[1]. In the trial, where 90% of patients had already had their thyroid removed, the label notes that 49% on Caprelsa needed a higher dose of thyroid hormone replacement, against 17% on placebo[1].
Blurred vision (9% against 1%) and corneal deposits seen on slit lamp exams were also reported, and since approval, artery aneurysms, dissections and ruptures have been reported[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Vandetanib
The dose is 300mg by mouth once a day, with or without food, until the cancer grows or side effects become too much[1]. A missed dose is not taken within 12 hours of the next one. Tablets are not crushed; for people who cannot swallow them, a tablet can be stirred in 2 ounces of plain water for about 10 minutes, swallowed right away, and the rest rinsed down with 4 more ounces of water, and the same mixture can go through a nasogastric or gastrostomy tube[1].
For grade 3 or worse side effects the dose drops to 200mg and then to 100mg, and Caprelsa is paused when the QTcF passes 500ms until it falls below 450ms[1]. People with moderate kidney impairment start at 200mg; the label does not recommend Caprelsa with severe kidney impairment or with moderate or severe liver impairment[1].
The label says to avoid strong CYP3A4 inducers such as rifampicin and St. John's wort, and drugs that prolong the QT interval, including antiarrhythmics such as amiodarone and sotalol and others such as clarithromycin, methadone, moxifloxacin and haloperidol. Caprelsa raises blood levels of metformin and digoxin, so those need closer watching[1]. Caprelsa comes as 100mg and 300mg tablets in bottles of 30[1].
Availability and cost
Only available as the brand-name product.
A daily oral cancer drug sold through a specialty pharmacy. The label gives no price. Sanofi's CAPRELSA Access Support offers a copay program for commercially insured patients, free drug for some uninsured or underinsured patients and a short-term interim supply.
Help paying for Caprelsa
With private insurance, the drugmaker's copay card can lower what you pay for Caprelsa. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 3 charity funds for the conditions it treats were open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Co-Pay Assistance Program: commercially insured patients whose out-of-pocket costs for Caprelsa are over $50 may get help up to the program maximum per calendar year. The page does not state the maximum or list government-plan exclusions.
For: private insurance · source - Free medicine program
CAPRELSA Patient Assistance Program: Caprelsa free of charge, if approved, for patients who are uninsured or whose plan does not cover Caprelsa and whose physician recommends it. No income limit is published; an application form is on the page.
For: no insurance, underinsured · source - Bridge or quick-start supply
Interim Access Program: a short-term free supply for insured patients who medically need Caprelsa and face a barrier such as prior authorization, an insurance appeal or travel outside their coverage area. Length and quantity are not stated.
The official page does not say who qualifies. Ask the program. · source - Insurance and case manager help
CAPRELSA Access Support runs through Biologics, Inc., a specialty pharmacy, with 24/7 access to a clinical oncology pharmacist. Pharmacy questions: 1-800-850-4306.
The official page does not say who qualifies. Ask the program. · source
Good to know: Read on caprelsa.com on November 14, 2026. No hours, copay maximum, income limit or government-plan exclusions are published. The site does not mention a REMS, which matches the FDA's September 25, 2025 removal.
Charity funds
- From a charity · The Assistance FundThyroid Cancer fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and charity fund for Medullary Thyroid Cancer →
Every program and charity fund for Familial Medullary Thyroid Carcinoma →
Access and eligibility
Approved for symptomatic or progressive medullary thyroid cancer in people whose cancer cannot be removed by surgery and is locally advanced or has spread[1]. The label asks doctors to use Caprelsa in slow-growing cancer without symptoms only after careful consideration of its risks, and it does not limit use to RET-mutant cancer. Safety and efficacy in children have not been established[1]. Caprelsa is not used in congenital long QT syndrome, is not started when the QTcF is above 450ms, and is not recommended with severe kidney impairment or moderate or severe liver impairment[1].
Source: CAPRELSA Access Support
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
The pivotal trial (D4200C00058, NCT00410761) randomized 331 people with unresectable locally advanced or metastatic medullary thyroid cancer to Caprelsa 300mg (231) or placebo (100)[1][4]. Caprelsa lengthened progression-free survival (hazard ratio 0.35): the median was not reached on Caprelsa against 16.4 months on placebo[1]. Results were similar in people who had symptoms or whose cancer had grown in the 6 months before joining.
Of people on Caprelsa, 44% had their tumors shrink, all partial responses, against 1% on placebo[1]. Overall survival did not differ: the median was 81.6 months on Caprelsa and 80.4 months on placebo (hazard ratio 0.99). The label notes that 79% of placebo patients chose open-label Caprelsa after their cancer grew[1]. Caprelsa was later a comparator in LIBRETTO-531 (NCT04211337), where people with RET-mutant medullary thyroid cancer who had not taken a kinase inhibitor got Retevmo or a doctor's choice of cabozantinib or vandetanib[7].
Development history
AstraZeneca developed vandetanib under the code ZD6474[4][5]. The FDA approved Caprelsa on April 6, 2011 under NDA 022405[2], and the FDA says a REMS safety program for heart rhythm monitoring was required at approval[3]. AstraZeneca announced on July 27, 2015 that it would sell the global rights to Caprelsa to Genzyme[5], and the current label names Genzyme Corporation, a Sanofi company[1].
The label updated in May 2025 added a warning for osteonecrosis, including of the jaw[1]. On September 25, 2025, the FDA removed the REMS, saying the special restrictions were no longer necessary and that REMS assessments found no cases of torsades de pointes or unexplained sudden death among US patients[3]. The boxed warning remains on the current label, revised in January 2026[1].
Explore Medullary Thyroid Cancer and Familial Medullary Thyroid Carcinoma trials
Other Medullary Thyroid Cancer & Familial Medullary Thyroid Carcinoma treatments
Common questions about Vandetanib
▸What is Vandetanib (Caprelsa)?
A once-daily pill for medullary thyroid cancer that is causing symptoms or growing and cannot be removed by surgery or has spread[1]. Caprelsa was approved by the FDA on April 6, 2011[2]. Its label carries a boxed warning for QT prolongation, torsades de pointes and sudden death. The FDA removed the extra REMS safety program on September 25, 2025 and left the prescribing information the same[3].
▸How does Vandetanib work?
Medullary thyroid cancer starts in the thyroid's C cells, the cells that make the hormone calcitonin. Many of these cancers are driven by a change in the RET gene, which keeps a growth signal switched on. Vandetanib blocks the tyrosine kinase activity of RET, of the VEGF receptors that tumors use to grow new blood vessels, and of the EGF receptor, along with several other kinases (BRK, TIE2 and members of the EPH and Src families)[1]. In laboratory and mouse studies, it cut the growth of new tumor blood vessels and slowed tumor growth and spread[1]. The Caprelsa label does not require a RET test before treatment. Vandetanib leaves the body slowly, and the Medication Guide says side effects can continue after treatment stops[1].
▸What are the side effects of Vandetanib?
Caprelsa carries a boxed warning: it can prolong the QT interval, and torsades de pointes and sudden death have occurred[1]. The label says not to use it in people with low calcium, potassium or magnesium or long QT syndrome, and Caprelsa is contraindicated in congenital long QT syndrome[1]. In the randomized trial, 14% on Caprelsa had a prolonged QT on their ECG against 1% on placebo, and the label's footnote reports that 69% had a QTcF over 450ms and 7% over 500ms[1]. Other label warnings cover severe skin reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome, sun sensitivity lasting up to 4 months after stopping, lung inflammation, blocked blood flow to the brain, called ischemic cerebrovascular events (1.3% against 0%), serious bleeding, heart failure, severe diarrhea (grade 3 or worse in 11%), high blood pressure, a brain swelling syndrome called RPLS, kidney failure, slow wound healing, osteonecrosis of the jaw and harm to an unborn baby[1]. In the trial of 231 people on Caprelsa and 99 on placebo, side effects in more than 20% and at least 5 points more common than placebo were diarrhea or colitis (57% against 27%), rash (53% against 12%), acne-like rash (35% against 7%), high blood pressure (33% against 5%), nausea (33% against 16%), headache (26% against 9%), upper respiratory infections (23% against 16%), decreased appetite (21% against 12%) and abdominal pain (21% against 11%)[1]. Lab changes included low calcium (57% against 25%), raised ALT, a liver enzyme (51% against 19%) and low blood sugar (24% against 7%)[1]. Side effects led 12% on Caprelsa to stop treatment, against 3.0% on placebo[1]. In the trial, where 90% of patients had already had their thyroid removed, the label notes that 49% on Caprelsa needed a higher dose of thyroid hormone replacement, against 17% on placebo[1]. Blurred vision (9% against 1%) and corneal deposits seen on slit lamp exams were also reported, and since approval, artery aneurysms, dissections and ruptures have been reported[1].
▸How is Vandetanib taken?
The dose is 300mg by mouth once a day, with or without food, until the cancer grows or side effects become too much[1]. A missed dose is not taken within 12 hours of the next one. Tablets are not crushed; for people who cannot swallow them, a tablet can be stirred in 2 ounces of plain water for about 10 minutes, swallowed right away, and the rest rinsed down with 4 more ounces of water, and the same mixture can go through a nasogastric or gastrostomy tube[1]. For grade 3 or worse side effects the dose drops to 200mg and then to 100mg, and Caprelsa is paused when the QTcF passes 500ms until it falls below 450ms[1]. People with moderate kidney impairment start at 200mg; the label does not recommend Caprelsa with severe kidney impairment or with moderate or severe liver impairment[1]. The label says to avoid strong CYP3A4 inducers such as rifampicin and St. John's wort, and drugs that prolong the QT interval, including antiarrhythmics such as amiodarone and sotalol and others such as clarithromycin, methadone, moxifloxacin and haloperidol. Caprelsa raises blood levels of metformin and digoxin, so those need closer watching[1]. Caprelsa comes as 100mg and 300mg tablets in bottles of 30[1].
▸Is Vandetanib FDA approved?
Yes. The FDA approved Caprelsa on April 6, 2011 for symptomatic or progressive medullary thyroid cancer that cannot be removed by surgery and is locally advanced or has spread.
Hereditary or not: the label's indication does not separate inherited from non-inherited medullary thyroid cancer and does not require a RET test.
Slow-growing cancer: the label asks doctors to weigh its risks carefully before using it when the cancer has no symptoms and grows slowly.
Children: safety and efficacy have not been established.
Source: Caprelsa prescribing information
▸Does Caprelsa still have a REMS program?
No. The FDA removed the Caprelsa REMS on September 25, 2025, and prescribers no longer need special certification[3].
Why: the FDA said the special restrictions were no longer necessary, and REMS assessments found no cases of torsades de pointes or unexplained sudden death among US patients.
What stays: the FDA said the prescribing information stays the same, and the current label still carries the boxed warning and the ECG and blood test schedule.
▸What heart tests are needed on Caprelsa?
The label calls for an ECG and blood potassium, calcium, magnesium and TSH before starting, at 2 to 4 weeks, at 8 to 12 weeks, and every 3 months after that[1].
Not started: when the QTcF is above 450ms.
Paused: when the QTcF passes 500ms, then restarted at a lower dose once it falls below 450ms.
Potassium: kept at 4mEq/L or higher.
More often: during diarrhea.
Repeated from the start: after a dose cut for QT prolongation or a break of more than 2 weeks.
Source: Caprelsa prescribing information
▸How well did Caprelsa work for medullary thyroid cancer?
In its placebo-controlled trial, Caprelsa delayed cancer growth: the median progression-free survival was not reached on Caprelsa against 16.4 months on placebo (hazard ratio 0.35)[1].
Tumor shrinkage: 44% on Caprelsa against 1% on placebo, all partial responses.
Overall survival: no difference, with medians of 81.6 and 80.4 months.
Crossover: 79% of placebo patients took open-label Caprelsa after their cancer grew.
Source: Caprelsa prescribing information
▸Is there help paying for Caprelsa?
Sanofi's CAPRELSA Access Support, run through the specialty pharmacy Biologics, Inc., offers copay help, free drug and a short-term interim supply[11].
Copay: for commercially insured patients whose out-of-pocket cost is over $50, up to a yearly maximum the page does not state.
Free drug: for eligible patients who are uninsured or whose plan does not cover Caprelsa.
Interim supply: a short-term free supply for insured patients waiting on a prior authorization or appeal.
Phone: 1-800-367-4999 for patient assistance.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Genzyme Corporation via DailyMed · 2026-10-30. CAPRELSA- vandetanib tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03
- U.S. Food and Drug Administration · 2011-04-06. CAPRELSA approval history, NDA 022405. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022405
- U.S. Food and Drug Administration · 2025-09-25. FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib). https://www.fda.gov/news-events/press-announcements/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib
- ClinicalTrials.gov. An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer. https://clinicaltrials.gov/study/NCT00410761
- AstraZeneca · 2015-07-27. AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine. https://www.astrazeneca.com/media-centre/press-releases/2015/astrazeneca-genzyme-rare-disease-medicine-caprelsa-27072015.html
- Exelixis, Inc. via DailyMed · 2025-10-18. COMETRIQ- cabozantinib kit / COMETRIQ- cabozantinib capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34
- Eli Lilly and Company via DailyMed · 2026-09-11. RETEVMO- selpercatinib capsule RETEVMO- selpercatinib tablet, coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828
- Rigel Pharmaceuticals via DailyMed · 2025-12-30. GAVRETO- pralsetinib capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16edd46e-28b8-f06d-e063-6394a90ae31b
- U.S. Food and Drug Administration · 2023-07-20. NDA 213721/S-014 supplement approval, withdrawal of accelerated approval indication (GAVRETO). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213721Orig1s014ltr.pdf
- Sanofi. Patient Resources and Support | CAPRELSA.com. https://www.caprelsa.com/pt_resources_and_support.asp
- Sanofi. Patient Resources and Support | CAPRELSA.com (financial assistance). https://www.caprelsa.com/pt_resources_financial_assistance.asp